BIOTRICITY INC. (BTCY)
2025-06-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 3,873,993 | 3,619,108 | 3,266,846 | 3,201,743 |
| Cost of revenue | 757,193 | 855,140 | 807,672 | 838,575 |
| Gross profit | 3,116,800 | 2,763,968 | 2,459,174 | 2,363,168 |
| Selling, general and administrative expenses | 2,138,692 | 2,381,734 | 2,248,864 | 2,966,119 |
| Research and development expenses | 696,163 | 551,216 | 517,982 | 513,895 |
| Total operating expenses | 2,834,855 | 2,932,950 | 2,766,846 | 3,480,014 |
| (loss) profit from operations | 281,945 | -168,982 | -307,672 | -1,116,846 |
| Interest expense | 850,254 | - | - | - |
| Gain (loss) upon convertible promissory notes conversion and redemption note 9 | 8,433 | -17,357 | -4,690 | -127,611 |
| Change in fair value of derivative liabilities note 8 | -25,200 | 32,339 | -193,757 | -306,862 |
| Accretion and amortization expenses note 5,6 | -153,572 | -291,128 | -339,888 | -1,144,728 |
| Other income (expense) note 9 | 66,671 | 65,512 | 36,314 | -229,800 |
| Interest expense | - | 849,538 | 752,075 | 768,673 |
| Net loss before income taxes | -671,977 | -1,229,154 | -1,561,768 | -3,694,520 |
| Income taxes note 3 | - | - | - | - |
| Net loss before dividends | -671,977 | -1,229,154 | -1,561,768 | -3,694,520 |
| Deemed dividends note 9 | - | - | - | -3,054,680 |
| Preferred stock dividends | 82,316 | 89,392 | 91,261 | 199,092 |
| Net loss attributable to common stockholders | -754,293 | -1,318,546 | -1,653,029 | -6,948,292 |
| Translation adjustment | -36,169 | 76,680 | -129,376 | 23,583 |
| Comprehensive loss | -790,462 | -1,241,866 | -1,782,405 | -6,924,709 |
| Loss per share, basic | -0.029 | -0.054 | -0.073 | -0.49 |
| Loss per share, diluted | -0.029 | -0.054 | -0.073 | -0.49 |
| Weighted average number of common shares outstanding - basic | 26,284,734 | 24,232,369 | 22,493,626 | 14,169,441 |
| Weighted average number of common shares outstanding - diluted | 26,284,734 | 24,232,369 | 22,493,626 | 14,169,441 |